OR WAIT null SECS
Catalent Pharma Solutions
, company in drug development solutions and advanced delivery technologies for pharmaceutical, biologic and consumer health products, today announced two joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses. Catalent continues to expand its global leadership by providing access to drug delivery and clinical trial capabilities for customers in Asia Pacific. The company intends to make additional investments in these two facilities over the next several years to broaden its offerings in the Chinese market.
First, Catalent has agreed to acquire, pending regulatory approvals, a majority share in Haining-based, privately held Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd. The business produces nutritional softgel products for Chinese and Asia Pacific markets, and employs 120 staff. Catalent intends to work with regulators for future expansion into OTC and prescription softgel manufacturing in China.
In the second announcement, Catalent and ShangPharma Corporation, a leading China-based pharmaceutical and biotechnology research and development outsourcing company, have formed a joint-venture called Catalent (Shanghai) Clinical Trial Supplies Co., Ltd. A new 31,000 sq ft facility in Shanghai, which is currently under construction, will be the first in China to provide end-to-end solutions for clinical trial supplies, including comparator sourcing, primary and secondary packaging and labeling, and storage and distribution.
Commenting on both investments, Catalent’s President & CEO, John Chiminski said, “As part of our growth strategy, these initial steps enable us to better serve the important Chinese market for both global and domestic customers. Our clients and their patients will benefit from access to Catalent’s advanced technologies and solutions, together with best-in-class innovation, reliable supply and quality compliance.”
“We are delighted to be working with Catalent, a world leader in drug development services and clinical supply services,” said Michael Hui, founder and CEO of ShangPharma. “This cooperation will enable both ShangPharma and Catalent to better serve our multinational pharmaceutical customers through tailored, integrated solutions.”
The Chairman & CEO of Zhejiang Jiang Yuan Tang Biotechnology Co., Ltd, Jiang Renfei commented “The combination of Catalent’s unparalleled track record of Softgel innovation and commercial success, and our deep understanding of the local market, will provide extensive benefits for our customers”.
No other terms of the transactions have been disclosed.